Khresmoi Professional: Multilingual Semantic Search for Medical Professionals

There is increasing interest in and need for innovative solutions to medical search. In this paper we present the EU funded Khresmoi medical search and access system, currently in year 3 of 4 of development across 12 partners . The Khresmoi system uses a component based architecture housed in the cloud to allow for the development of several innovative applications to support target users medical information needs. The Khresmoi search systems based on this architecture have been designed to support the multilingual and multimod al information needs of three target groups the general public, general practitioners and consultant radiologists. In this paper we focus on the presentation of the systems to support the latter two groups using semantic, multilingual text and image based (including 2D and 3D radiology images) search

Khresmoi: Multimodal Multilingual Medical Information Search

Khresmoi is a European Integrated Project developing a multilingual multimodal search and access system for medical and health information and documents. It addresses the challenges of searching through huge amounts of medical data, including general medical information available on the internet, as well as radiology data in hospital archives. It is developing novel semantic search and visual search techniques for the medical domain. At the MIE Village of the Future, Khresmoi proposes to have two interactive demonstrations of the system under development, as well as an overview oral presentation and potentially some poster presentation

Khresmoi – multilingual semantic search of medical text and images

The Khresmoi project is developing a multilingual multimodal search and access system for medical and health information and documents. This scientific demonstration presents the current state of the Khresmoi integrated system, which includes components for text and image annotation, semantic search, search by image similarity and machine translation. The flexibility in adapting the system to varying requirements for different types of medical information search is demonstrated through two instantiations of the system, one aimed at medical professionals in general and the second aimed at radiologists. The key innovations of the Khresmoi system are the integration of multiple software components in a flexible scalable medical search system, the use of annotation cycles including manual correction to improve semantic search, and the possibility to do large scale visual similarity search on 2D and 3D (CT, MR) medical images

Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir

International audienceBackground. Quantitative hepatitis B core-related antigen (qHBcrAg) or antihepatitis B core antibody (qAnti-HBc) could be useful in monitoring liver fibrosis evolution during chronic hepatitis B virus (HBV) infection, yet it has not been assessed in human immunodeficiency virus (HIV)-HBV-coinfected patients undergoing treatment with tenofovir (TDF). Methods. One hundred fifty-four HIV-HBV-infected patients initiating a TDF-containing antiretroviral regimen were prospectively followed. The qHBcrAg and qAnti-HBc and liver fibrosis assessment were collected every 6-12 months during TDF. Hazard ratios (HRs) assessing the association between qHBcrAg/qAnti-HBc and transitions from none/mild/significant fibrosis to advanced fibrosis/cirrhosis (progression) and from advanced fibrosis/cirrhosis to none/mild/significant fibrosis (regression) were estimated using a time-homogeneous Markov model. Results. At baseline, advanced liver fibrosis/cirrhosis was observed in 40 (26%) patients. During a median follow-up of 48 months (interquartile range, 31-90), 38 transitions of progression (IR = 7/100 person-years) and 34 transitions of regression (IR = 6/100 person-years) were observed. Baseline levels of qHBcrAg and qAnti-HBc were not associated with liver fi-brosis progression (adjusted-HR per log 10 U/mL = 1.07, 95% confidence interval [CI] = 0.93-1.24; adjusted-HR per log 10 Paul-Ehrlich-Institute [PEI] U/mL = 0.85, 95% CI = 0.70-1.04, respectively) or regression (adjusted-HR per log 10 U/mL = 1.17, 95% CI = 0.95-1.46; adjusted-HR per log 10 PEI U/mL = 0.97, 95% CI = 0.78-1.22, respectively) after adjusting for age, gender, duration of antiretroviral therapy, protease inhibitor-containing antiretroviral therapy, and CD4 + /CD8 + ratio. Nevertheless, changes from the previous visit of qAnti-HBc levels were associated with liver fibrosis regression (adjusted-HR per log 10 PEIU/ mL change = 5.46, 95% CI = 1.56-19.16). Conclusions. Baseline qHBcrAg and qAnti-HBc levels are not associated with liver fibrosis evolution in TDF-treated HIV-HBV coinfected patients. The link between changes in qAnti-HBc levels during follow-up and liver fibrosis regression merits further study